Skip to content

Study · In vitro (cells) · 2014

5 results

Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.

Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Monges G, Garcia S, Ferone D, Florio T, Enjalbert A and 5 more

Show all authors

Moutardier V, Schonbrunn A, Gerard C, Barlier A, Saveanu A

Endocrine-related cancer10 Jul 2014Cited by 46 (Europe PMC)

PMID25012983 (opens in a new tab)DOI10.1530/erc-14-0086 (opens in a new tab)PepBankPUB-25012983
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human pNET primary cells, pasireotide inhibited CgA secretion at least as efficiently as octreotide at 1-10 nM.

    In plain wordsIn cells from human pancreatic tumors, pasireotide reduced chromogranin A secretion at least as efficiently as octreotide.

    Peptide
    Pasireotide
    Outcome
    Direction not reportedChromogranin A secretion
    Study

    humann: not reported in source

    Primary pancreatic neuroendocrine tumor cells
    Comparator
    Octreotide
    Outcome group
    Endogenous peptide levels · Cancer
    Studied dose
    1-10 nMAs given in this study (human).

    Source sentences

    Summary
    At clinically relevant concentrations (1-10 nM), pasireotide was at least as efficient as octreotide in inhibiting CgA secretion and cell viability through caspase-dependent apoptosis during short treatments, irrespective of the expression levels of the different sst receptors or the WHO grade of the parental tumor.
    1 context sentence
    Summary · context
    Our aim was to compare the effects of pasireotide and octreotide on cell survival, chromogranin A (CgA) secretion, and sst2 phosphorylation/trafficking in pancreatic NET (pNET) primary cells from 15 tumors.
  2. 02LabIn vitro (cells)Efficacy outcome

    In human pNET primary cells, pasireotide inhibited cell viability through caspase-dependent apoptosis at least as efficiently as octreotide at 1-10 nM.

    In plain wordsIn cells from human pancreatic tumors, pasireotide reduced cell survival through apoptosis at least as efficiently as octreotide.

    Peptide
    Pasireotide
    Outcome
    Direction not reportedCell viability
    Study

    humann: not reported in source

    Primary pancreatic neuroendocrine tumor cells
    Comparator
    Octreotide
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1-10 nMAs given in this study (human).

    Source sentences

    Summary
    At clinically relevant concentrations (1-10 nM), pasireotide was at least as efficient as octreotide in inhibiting CgA secretion and cell viability through caspase-dependent apoptosis during short treatments, irrespective of the expression levels of the different sst receptors or the WHO grade of the parental tumor.
    1 context sentence
    Summary · context
    Our aim was to compare the effects of pasireotide and octreotide on cell survival, chromogranin A (CgA) secretion, and sst2 phosphorylation/trafficking in pancreatic NET (pNET) primary cells from 15 tumors.
  3. 03LabIn vitro (cells)Mechanism

    In human pNET cells, pasireotide did not phosphorylate sst2, unlike octreotide.

    In plain wordsIn cells from human pancreatic tumors, pasireotide did not phosphorylate sst2, unlike octreotide.

    Peptide
    Pasireotide
    Outcome
    Decreasesst2 phosphorylation
    Study

    humann: not reported in source

    Primary pancreatic neuroendocrine tumor cells
    Comparator
    Octreotide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, unlike octreotide, which induces a rapid and persistent partial internalization of sst2 associated with its phosphorylation on Ser341/343, pasireotide did not phosphorylate sst2 and induced a rapid and transient internalization of the receptor followed by a persistent recycling at the cell surface.
    1 context sentence
    Summary · context
    Our aim was to compare the effects of pasireotide and octreotide on cell survival, chromogranin A (CgA) secretion, and sst2 phosphorylation/trafficking in pancreatic NET (pNET) primary cells from 15 tumors.
  4. 04LabIn vitro (cells)Mechanism

    In human pNET cells, pasireotide induced rapid transient sst2 internalization, unlike the persistent partial internalization with octreotide.

    In plain wordsIn cells from human pancreatic tumors, pasireotide caused brief receptor internalization, while octreotide caused persistent partial internalization.

    Peptide
    Pasireotide
    Outcome
    Not applicablesst2 internalization
    Study

    humann: not reported in source

    Primary pancreatic neuroendocrine tumor cells
    Comparator
    Octreotide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, unlike octreotide, which induces a rapid and persistent partial internalization of sst2 associated with its phosphorylation on Ser341/343, pasireotide did not phosphorylate sst2 and induced a rapid and transient internalization of the receptor followed by a persistent recycling at the cell surface.
    1 context sentence
    Summary · context
    Our aim was to compare the effects of pasireotide and octreotide on cell survival, chromogranin A (CgA) secretion, and sst2 phosphorylation/trafficking in pancreatic NET (pNET) primary cells from 15 tumors.
  5. 05LabIn vitro (cells)Mechanism

    In human pNET cells, pasireotide induced persistent sst2 recycling at the cell surface after transient internalization.

    In plain wordsIn cells from human pancreatic tumors, pasireotide caused persistent receptor recycling to the cell surface.

    Peptide
    Pasireotide
    Outcome
    Increasesst2 recycling
    Study

    humann: not reported in source

    Primary pancreatic neuroendocrine tumor cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, unlike octreotide, which induces a rapid and persistent partial internalization of sst2 associated with its phosphorylation on Ser341/343, pasireotide did not phosphorylate sst2 and induced a rapid and transient internalization of the receptor followed by a persistent recycling at the cell surface.
    1 context sentence
    Summary · context
    Our aim was to compare the effects of pasireotide and octreotide on cell survival, chromogranin A (CgA) secretion, and sst2 phosphorylation/trafficking in pancreatic NET (pNET) primary cells from 15 tumors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Versions 2 to 3

    27 Oct 2026, 16:36 UTC

    The same notice was added 2 times, first on 27 Oct 2026, 16:36 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.